Core Viewpoint - Mingde Biological is planning two acquisitions within a month, including a 51% stake in Hunan Lanyi Medical Equipment Co., Ltd. for 35.7 million yuan, despite Hunan Lanyi's negative net assets and consecutive losses [1][2]. Group 1: Acquisition Details - The acquisition of Hunan Lanyi aims to enhance synergy and core competitiveness, focusing on complementary industry chains to improve comprehensive service capabilities [1][2]. - Hunan Lanyi, established in September 2020, specializes in IVD instruments and reagents, recognized as a national high-tech enterprise and a "little giant" in specialized fields [2]. - The acquisition structure includes Mingde acquiring 51% of Hunan Lanyi, while related parties will hold an additional 20%, with plans for full control if performance targets are met [2][3]. Group 2: Financial Performance and Projections - Hunan Lanyi reported a net asset of -62.42 million yuan and consecutive losses of 20.68 million yuan in 2024 and 23.98 million yuan in the first three quarters of 2025 [1]. - Mingde Biological's projected net profit for 2025 is expected to decline by 75.85% to 83.9%, ranging from 12 million to 18 million yuan, primarily due to decreased investment income and increased credit impairment losses [5]. - The financial performance of Wuhan Bikaier, another target for acquisition, shows stable revenue and profit, with 2023 revenues of 168 million yuan and net profit of 12.64 million yuan [4].

Core Insights - Mingde Biological has initiated two equity acquisitions to focus on emergency rescue and in vitro diagnostic instruments, driven by declining COVID-19 testing business and increasing competition in the in vitro diagnostic industry [1][6] Group 1: Acquisition Details - On December 31, 2025, Mingde Biological signed a framework agreement with Blue Sail Medical to acquire 100% of Wuhan Bikaier Rescue Supplies Co., Ltd. for cash [2] - Wuhan Bikaier, a leader in emergency rescue, reported a revenue of 165 million yuan and a net profit of 13.87 million yuan in 2024, with a revenue of 75.8 million yuan and a net profit of 7.52 million yuan in the first half of 2025 [2] - The acquisition aims to enhance Mingde Biological's market position in critical care by integrating emergency protection services into industrial and household scenarios [2] Group 2: Second Acquisition - On January 20, 2026, Mingde Biological announced a plan to acquire 51% of Hunan Lanyi Medical Equipment Co., Ltd. for a total price of 35.71 million yuan, making it a subsidiary [3][4] - Hunan Lanyi focuses on IVD instruments and has significant potential in the market, particularly in glycosylated hemoglobin testing [4] - The acquisition includes performance commitments, with Hunan Lanyi required to achieve an average net profit of at least 20 million yuan over three years to trigger further acquisition phases [5] Group 3: Financial Performance - Mingde Biological's revenue has faced significant declines, with 2023 and 2024 revenues at approximately 750 million yuan and 350 million yuan, representing year-on-year declines of 92.88% and 53.30% respectively [6] - The company reported a net profit of approximately 74.93 million yuan in 2023, down 9.22% year-on-year, and a net profit of about 74.52 million yuan in 2024, down 0.54% year-on-year [6] - As of September 30, 2025, the company's cash reserves were 184 million yuan, a decrease of 63% from the beginning of the period [6]

南财智讯1月30日电，明德生物发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 1200万元—1800万元，同比预减75.85%—83.90%；预计2025年全年归属于上市公司股东的扣除非经常 性损益的净利润为-9800万元—-7800万元。公司归属于上市公司股东的净利润同比下滑，主要受投资收 益、其他收益大幅下降，以及信用减值损失增加的影响。报告期内，公司获得的政府补助金额较上年同 期减少逾4000万元；受国内金融市场利率持续下行、公司理财产品收益率同比走低等因素影响，投资收 益较上年同期减少逾3000万元；公司逾期应收账款回款金额低于上年，单独进行减值测试的应收款项减 值准备转回金额较上年减少逾3000万元，从而导致信用减值损失增加。 ...

Financial Performance Expectations - The company expects a net profit of between 12 million to 18 million yuan for 2025, representing a decline of 75.85% to 83.90% compared to the previous year[4]. - The net profit attributable to shareholders is projected to decrease by over 50% year-on-year[2]. - The net profit after deducting non-recurring gains and losses is projected to be between -98 million to -78 million yuan, an increase of 30.17% to 44.42% compared to the previous year[4]. - Basic earnings per share are expected to be between 0.05 to 0.08 yuan, down from 0.33 yuan in the previous year[4]. Revenue and Income Changes - Government subsidies received decreased by over 40 million yuan compared to the same period last year[3]. - Investment income is expected to decline by over 30 million yuan year-on-year due to lower yields from financial products[3]. - The company anticipates a credit impairment loss increase due to lower collection of overdue receivables and reduced reversal of impairment provisions[3]. Operational Strategy and Caution - The company will continue to optimize product and customer structures while enhancing cost control and operational quality[5]. - This earnings forecast is based on preliminary calculations and has not been audited by an external auditor[6]. - Investors are advised to exercise caution and consider investment risks due to the preliminary nature of the financial data[6].

Group 1 - The company Mingde Bio is planning to acquire 100% equity of Wuhan Bikaier Rescue Supplies Co., Ltd. from Bluefan Medical Co., Ltd. through a cash transaction [1] - This transaction is expected to constitute a major asset restructuring but will not lead to a restructuring listing, involve share issuance, or constitute a related party transaction [1] - The company is currently advancing auditing, evaluation, and due diligence processes, and no formal agreement has been signed yet; the specific plan is still under discussion [1]

特别提示： 1、武汉明德生物科技股份有限公司（以下简称"公司"）于 2025 年 12 月 31 日披露了《关于筹划重大资产重组暨签署<股权收购意向协议>的提示性公告》 （公告编号：2025-056），已对本次交易涉及的相关事项进行了说明。 证券代码：002932 证券简称：明德生物 公告编号：2026-005 武汉明德生物科技股份有限公司 关于重大资产重组进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 三、风险提示 2、本次交易相关工作正在积极推进中，交易各方尚未签署正式协议。本次 交易尚存在较大不确定性，公司将根据相关事项的进展情况，分阶段及时履行信 息披露义务，敬请广大投资者关注公司后续公告，注意投资风险。 一、交易概述 公司拟以现金方式收购蓝帆医疗股份有限公司持有的武汉必凯尔救助用品 有限公司（以下简称"标的公司"）100%股权。本次交易完成后，标的公司将 成为公司的全资子公司。本次交易预计构成《上市公司重大资产重组管理办法》 规定的重大资产重组。本次交易拟采用现金方式，不构成重组上市，不涉及上市 公司发行股份。本次交易不构成关联交易，也不 ...

1月19日晚间，武汉本土医疗企业明德生物（SZ002932，股价19.31元，市值44.90亿元）公告称，与交 易对手方签署《关于蓝怡（湖南）医疗器械有限公司之收购协议》，拟以3570.10万元收购蓝怡（湖 南）医疗器械有限公司（以下简称湖南蓝怡）51%股权。 交易完成后，湖南蓝怡将成为明德生物的控股子公司，纳入公司合并报表范围。这一交易标志着深耕急 危重症诊断领域的明德生物正式切入慢病管理赛道。 《每日经济新闻》记者注意到，就在此前的2025年12月30日，明德生物公告称，拟现金收购蓝帆医疗 （SZ002382，股价5.93元，市值59.72亿元）旗下武汉必凯尔100%股权。两起并购间隔不到一个月。 分期收购+多重对赌 每经记者｜甄素静 每经编辑｜魏文艺 此前的2025年12月30日，明德生物宣布，公司已与蓝帆医疗签订《股权收购意向协议》，计划以现金形 式收购武汉必凯尔100%股权。交易完成后，武汉必凯尔成为明德生物的全资子公司。 据了解，武汉必凯尔是较早引入国际第一急救理念和技术的企业，主要从事以急救包为核心，全面布局 应急装备、应急单品和应急服务的应急救护业务。 接连两起并购动作，凸显了明德生物在主营业 ...

Group 1 - The core viewpoint of the article highlights Mingde Biological's recent acquisition plans, including the purchase of a 51% stake in Hunan Lanyi Medical Equipment Co., Ltd., following its acquisition of 100% of Wuhang Bikaier Rescue Supplies Co., Ltd. [1] - Hunan Lanyi is expected to remain in a loss position for 2024 and the first three quarters of 2025, indicating potential challenges for Mingde Biological's financial performance [1] - Mingde Biological has faced pressure on its performance, reporting a net profit loss for two consecutive years, which may be a driving factor behind its aggressive acquisition strategy [1]

Group 1 - The company, Mindray Bio-Medical Electronics Co., Ltd., announced an investment of 30 million yuan as a limited partner in the Wuhan Zesen Juxin No. 2 Venture Capital Partnership, with a total fund size of 95 million yuan [2][3] - The company holds a 31.5789% stake in the fund but will not participate in specific investment decisions [2] - The fund primarily invests in equity of unlisted companies within the artificial intelligence infrastructure and terminal industry chain, focusing on sectors like optical interconnection and semiconductors [3] Group 2 - The collaboration with a professional investment institution aims to leverage its resources and management capabilities to enhance the company's investment layout and share in the growth dividends of emerging sectors [3] - The investment is fully funded by the company's own capital [3] - For the first three quarters of 2025, the company reported total operating revenue of 227 million yuan, reflecting a year-on-year growth of 0.53% [3]

Core Viewpoint - Mingde Bio plans to acquire 51% of Hunan Lanyi Medical Instrument Co., Ltd. for 35.71 million yuan, aiming to expand its medical service ecosystem and enhance its capabilities in chronic disease management [1][2]. Group 1: Acquisition Details - The acquisition will occur in two phases, with the first phase involving the purchase of 51% equity for 35.71 million yuan, making Hunan Lanyi a subsidiary of Mingde Bio [1][3]. - The transaction structure includes a capital increase of 20 million yuan for 28.57% equity and a purchase of 15.71 million yuan for 22.43% equity from the existing shareholders [3]. - If Hunan Lanyi meets performance conditions from 2026 to 2028, Mingde Bio will acquire the remaining 49% equity [1][3]. Group 2: Hunan Lanyi Overview - Hunan Lanyi, established in September 2020, focuses on the R&D and production of IVD instruments and reagents, particularly in glycated hemoglobin testing [2]. - The company reported revenues of 30.66 million yuan and a net loss of 23.98 million yuan for the first nine months of 2025, indicating growth potential due to increasing demand in the healthcare sector [2]. Group 3: Strategic Implications - The acquisition aims to create a comprehensive medical service platform that integrates acute and chronic disease management, enhancing service capabilities for healthcare institutions [4]. - Mingde Bio is also pursuing additional acquisitions, including a planned purchase of 100% of Wuhan Bikaier Rescue Supplies Co., Ltd. to further develop its acute care business segment [4].